Inventor · disambiguated record
Ann F. Cheung
Also filed as: CHEUNG ANN F
13 granted patents·48 pending applications·62 citations·filing 2018–2025
90Inventor score
Top patents by PatentIndex Score
61 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0296US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0396US11834506B2Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Dec 5, 2023·16 cites·18 claims
- 0496US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0594US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0691US11884732B2Proteins binding HER2, NKG2D and CD16DRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Jan 30, 2024·6 cites·15 claims
- 0787US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 0887US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0986US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1085US12157771B2Proteins binding NKG2D, CD16 and CLEC12ADRAGONFLY THERAPEUTICS INC·Filed 2021·Granted Dec 3, 2024·1 cites·21 claims
- 1180US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1279US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1379US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 1476US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1576US2023391877A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1676US2023357409A1Proteins binding nkg2d, cd16 and nectin4DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1775US2023227562A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1875US2023303702A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1974US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 2074US2024228625A1Proteins binding her2, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2174US2024166753A1Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2273US2024270861A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2373US2024360223A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2472US2024018266A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2571US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2666US2021292420A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2765US2021130474A1Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2864US2024124607A1Proteins binding nkg2d, cd16, and ceacam5MERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 2963US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3063US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3160US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3259US2022119533A1Heterodimeric fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3359US2021261668A1Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3458US2021130496A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3556US2020277383A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3656US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3755US2023220084A1Antibodies Targeting CLEC12A and Use ThereofDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3855US2023257467A1Proteins binding nkg2d, cd16 and egfrDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3953US2020002436A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4052US2020216544A1Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4152US2024117054A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4252US2024228628A9Antibodies targeting flt3 and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4351US2021206859A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4450US2020376034A1Antibody variable domains targeting cd33, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4550US2021363261A1Protein binding nkg2d, cd16 and a fibroblast activation proteinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4650US2022025037A1Antibody variable domains targeting dll3, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4749US2023272041A1Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused ProteinsDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4846US2021214436A1Multi-specific binding proteins and improvements thereonDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4946US2021238290A1Proteins binding nkg2d, cd16 and p-cadherinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5045US2020165344A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ann F. Cheung files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →